AstraZeneca PLC AZN on Thursday said interim results from the Phase 3 VOLGA trial showed that perioperative treatment with ...

(Reuters) -AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as $15 billion, Bloomberg News reported on Thursday, citing people ...

May 14 (Reuters) - AstraZeneca said on Thursday that a late-stage trial of Imfinzi, combined with a targeted therapy prior to ...

AstraZeneca’s first foray with PD-L1 inhibitor Imfinzi as a treatment for bladder cancer was a flop. | Following an FDA ...

Immunogenicity dragged on the efficacy of AstraZeneca’s rare endocrine disorder prospect in a phase 3 trial, causing the $800 ...

Pascal Soriot, Chief Executive Officer, AstraZeneca, said: “Building on our strong growth in the first half of the year and continued underlying demand for our medicines we are upgrading our FY 2024 ...

The advisory panel wasn't convinced that a clinical trial proved that early switching to camizestrant improved long-term ...

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Digital Health, a global leader in digital health solutions enhancing the patient experience, today announces a licensing agreement with AstraZeneca, a ...

AstraZeneca is the latest Big Pharma company looking to tap into agentic artificial intelligence (AI), inking a three-year ...

Holly has a degree in Medical Biochemistry from the University of Leicester. Her scientific interests include genomics, personalized medicine, and bioethics.View full profile Holly has a degree in ...

AstraZeneca AZN and AbbVie ABBV are leading U.S. drugmakers with strong positions in high-growth therapeutic areas like ...

Costco, Coca-Cola and AstraZeneca lead Zacks' top stock reports as strong earnings, growth drivers and pipeline momentum lift ...